Pharma Mar Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Pharma Mar heeft een totaal eigen vermogen van €182.2M en een totale schuld van €50.8M, wat de schuld-eigenvermogensverhouding op 27.9% brengt. De totale activa en totale passiva bedragen respectievelijk €333.1M en €151.0M.
Belangrijke informatie
27.9%
Verhouding schuld/eigen vermogen
€50.84m
Schuld
| Rente dekkingsratio | n/a |
| Contant | €144.39m |
| Aandelen | €182.17m |
| Totaal verplichtingen | €150.96m |
| Totaal activa | €333.13m |
Recente financiële gezondheidsupdates
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Recent updates
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Oct 16Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( €238.0M ) PHM } overtreffen de korte termijn passiva ( €89.4M ).
Langlopende schulden: De kortetermijnactiva PHM ( €238.0M ) overtreffen de langetermijnschulden ( €61.5M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: PHM heeft meer geld in kas dan de totale schuld.
Schuld verminderen: PHM had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.
Schuldendekking: De schuld van PHM wordt niet goed gedekt door de operationele kasstroom ( 3.2% ).
Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van PHM op haar schulden goed worden gedekt door EBIT.